JP2004532251A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004532251A5 JP2004532251A5 JP2002592879A JP2002592879A JP2004532251A5 JP 2004532251 A5 JP2004532251 A5 JP 2004532251A5 JP 2002592879 A JP2002592879 A JP 2002592879A JP 2002592879 A JP2002592879 A JP 2002592879A JP 2004532251 A5 JP2004532251 A5 JP 2004532251A5
- Authority
- JP
- Japan
- Prior art keywords
- mono
- residues
- alkyl
- aryl
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 329
- 125000003118 aryl group Chemical group 0.000 claims 320
- -1 gallium porphyrin Chemical class 0.000 claims 256
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 214
- 125000004404 heteroalkyl group Chemical group 0.000 claims 208
- 125000001072 heteroaryl group Chemical group 0.000 claims 195
- 125000000524 functional group Chemical group 0.000 claims 194
- 125000001188 haloalkyl group Chemical group 0.000 claims 190
- 125000000623 heterocyclic group Chemical group 0.000 claims 180
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims 160
- 150000001413 amino acids Chemical class 0.000 claims 121
- 229920000570 polyether Polymers 0.000 claims 113
- 239000004721 Polyphenylene oxide Substances 0.000 claims 105
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 92
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims 86
- 238000000034 method Methods 0.000 claims 84
- 150000002500 ions Chemical class 0.000 claims 67
- 229910052736 halogen Inorganic materials 0.000 claims 64
- GYHNNYVSQQEPJS-UHFFFAOYSA-N Gallium Chemical compound [Ga] GYHNNYVSQQEPJS-UHFFFAOYSA-N 0.000 claims 61
- 229910052733 gallium Inorganic materials 0.000 claims 57
- 125000005843 halogen group Chemical group 0.000 claims 56
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 49
- 150000001408 amides Chemical class 0.000 claims 39
- 150000002148 esters Chemical class 0.000 claims 35
- 125000003107 substituted aryl group Chemical group 0.000 claims 35
- 125000004429 atom Chemical group 0.000 claims 31
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 claims 26
- 101150065749 Churc1 gene Proteins 0.000 claims 26
- 102100038239 Protein Churchill Human genes 0.000 claims 26
- 125000001424 substituent group Chemical group 0.000 claims 24
- 229910021645 metal ion Inorganic materials 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- QGKVXWDADKTZHW-UHFFFAOYSA-N azaporphyrin Chemical compound C1=C(N=2)C=CC=2C=C(N=2)C=CC=2C=C(N2)C=CC2=CC2=CNC1=N2 QGKVXWDADKTZHW-UHFFFAOYSA-N 0.000 claims 15
- 125000004122 cyclic group Chemical group 0.000 claims 15
- 125000006239 protecting group Chemical group 0.000 claims 15
- 230000001225 therapeutic effect Effects 0.000 claims 15
- 210000001519 tissue Anatomy 0.000 claims 15
- 125000003342 alkenyl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 13
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 13
- 125000005194 alkoxycarbonyloxy group Chemical group 0.000 claims 13
- 125000005196 alkyl carbonyloxy group Chemical group 0.000 claims 13
- 125000000304 alkynyl group Chemical group 0.000 claims 13
- 125000003277 amino group Chemical group 0.000 claims 13
- 125000005199 aryl carbonyloxy group Chemical group 0.000 claims 13
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims 13
- 125000005200 aryloxy carbonyloxy group Chemical group 0.000 claims 13
- 125000004104 aryloxy group Chemical group 0.000 claims 13
- 125000000751 azo group Chemical group [*]N=N[*] 0.000 claims 13
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 13
- 229910002091 carbon monoxide Inorganic materials 0.000 claims 13
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate group Chemical group [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 claims 13
- 150000004820 halides Chemical class 0.000 claims 13
- 125000004438 haloalkoxy group Chemical group 0.000 claims 13
- 125000005842 heteroatom Chemical group 0.000 claims 13
- IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 claims 13
- 125000002462 isocyano group Chemical group *[N+]#[C-] 0.000 claims 13
- ZBKFYXZXZJPWNQ-UHFFFAOYSA-N isothiocyanate group Chemical group [N-]=C=S ZBKFYXZXZJPWNQ-UHFFFAOYSA-N 0.000 claims 13
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 13
- 125000000018 nitroso group Chemical group N(=O)* 0.000 claims 13
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims 13
- 125000005017 substituted alkenyl group Chemical group 0.000 claims 13
- 125000004426 substituted alkynyl group Chemical group 0.000 claims 13
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims 13
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 13
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M thiocyanate group Chemical group [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 claims 13
- 150000003839 salts Chemical class 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 10
- 125000000539 amino acid group Chemical group 0.000 claims 9
- 230000007935 neutral effect Effects 0.000 claims 9
- QPCDCPDFJACHGM-UHFFFAOYSA-N N,N-bis{2-[bis(carboxymethyl)amino]ethyl}glycine Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(=O)O)CCN(CC(O)=O)CC(O)=O QPCDCPDFJACHGM-UHFFFAOYSA-N 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 230000001678 irradiating effect Effects 0.000 claims 8
- 229910052751 metal Inorganic materials 0.000 claims 8
- 239000002184 metal Substances 0.000 claims 8
- 150000004032 porphyrins Chemical class 0.000 claims 8
- NCAJWYASAWUEBY-UHFFFAOYSA-N 3-[20-(2-carboxyethyl)-9,14-diethyl-5,10,15,19-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(21),2,4,6(24),7,9,11,13,15,17,19-undecaen-4-yl]propanoic acid Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 NCAJWYASAWUEBY-UHFFFAOYSA-N 0.000 claims 7
- 208000037803 restenosis Diseases 0.000 claims 7
- VAJVGAQAYOAJQI-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-3,8,13,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical compound N1C(C=C2C(C)=CC(N2)=CC=2C(=C(CCC(O)=O)C(=C3)N=2)C)=CC(C)=C1C=C1C(C)=C(CCC(O)=O)C3=N1 VAJVGAQAYOAJQI-UHFFFAOYSA-N 0.000 claims 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 6
- KNYADCQFKXFMEI-UHFFFAOYSA-N [N]1C2=CC=C1C=C(N1)C=C(Cl)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 Chemical compound [N]1C2=CC=C1C=C(N1)C=C(Cl)C1=CC([N]1)=CC=C1C=C(N1)C=CC1=C2 KNYADCQFKXFMEI-UHFFFAOYSA-N 0.000 claims 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 6
- 238000001514 detection method Methods 0.000 claims 6
- 238000002560 therapeutic procedure Methods 0.000 claims 6
- 201000001320 Atherosclerosis Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 150000002678 macrocyclic compounds Chemical class 0.000 claims 5
- 229910052763 palladium Inorganic materials 0.000 claims 5
- 150000004033 porphyrin derivatives Chemical class 0.000 claims 5
- 125000000542 sulfonic acid group Chemical group 0.000 claims 5
- 230000002792 vascular Effects 0.000 claims 5
- 229910052725 zinc Inorganic materials 0.000 claims 5
- 230000006378 damage Effects 0.000 claims 4
- 230000005292 diamagnetic effect Effects 0.000 claims 4
- 150000002170 ethers Chemical class 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 4
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 4
- 229910052738 indium Inorganic materials 0.000 claims 4
- 230000005298 paramagnetic effect Effects 0.000 claims 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims 4
- 229910052718 tin Inorganic materials 0.000 claims 4
- 229910052727 yttrium Inorganic materials 0.000 claims 4
- 201000004624 Dermatitis Diseases 0.000 claims 3
- 229910052782 aluminium Inorganic materials 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229910052742 iron Inorganic materials 0.000 claims 3
- 230000005291 magnetic effect Effects 0.000 claims 3
- 210000004509 vascular smooth muscle cell Anatomy 0.000 claims 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims 3
- 229920002554 vinyl polymer Polymers 0.000 claims 3
- ALSTYHKOOCGGFT-KTKRTIGZSA-N (9Z)-octadecen-1-ol Chemical compound CCCCCCCC\C=C/CCCCCCCCO ALSTYHKOOCGGFT-KTKRTIGZSA-N 0.000 claims 2
- NKCPOFKWOHNOHZ-UHFFFAOYSA-N 23H-porphyrin-2,3,5,7,21-pentacarboxylic acid Chemical class N1C(C=C2N=C(C=C3N(C(=C4C(O)=O)C(C(O)=O)=C3C(O)=O)C(O)=O)C=C2)=CC=C1C=C1C=C(C(=O)O)C4=N1 NKCPOFKWOHNOHZ-UHFFFAOYSA-N 0.000 claims 2
- VXISDLXPDHAQEK-UHFFFAOYSA-N 23h-porphyrin-2,3,5,7,8,21-hexacarboxylic acid Chemical class N1C(C=C2N=C(C=C3N(C(=C4C(O)=O)C(C(O)=O)=C3C(O)=O)C(O)=O)C=C2)=CC=C1C=C1C(C(=O)O)=C(C(O)=O)C4=N1 VXISDLXPDHAQEK-UHFFFAOYSA-N 0.000 claims 2
- MOTVYDVWODTRDF-UHFFFAOYSA-N 3-[7,12,17-tris(2-carboxyethyl)-3,8,13,18-tetrakis(carboxymethyl)-21,22-dihydroporphyrin-2-yl]propanoic acid Chemical class N1C(C=C2C(=C(CC(O)=O)C(=CC=3C(=C(CC(O)=O)C(=C4)N=3)CCC(O)=O)N2)CCC(O)=O)=C(CC(O)=O)C(CCC(O)=O)=C1C=C1C(CC(O)=O)=C(CCC(=O)O)C4=N1 MOTVYDVWODTRDF-UHFFFAOYSA-N 0.000 claims 2
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 claims 2
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical class CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 claims 2
- 229910052684 Cerium Inorganic materials 0.000 claims 2
- 108010035532 Collagen Proteins 0.000 claims 2
- 102000008186 Collagen Human genes 0.000 claims 2
- 229910052691 Erbium Inorganic materials 0.000 claims 2
- 229910052693 Europium Inorganic materials 0.000 claims 2
- 229910052689 Holmium Inorganic materials 0.000 claims 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 2
- 229910052765 Lutetium Inorganic materials 0.000 claims 2
- JGQGDUURWUDSDW-UHFFFAOYSA-N N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NN=C1C=C1C=CC4=N1 Chemical compound N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=NN=C1C=C1C=CC4=N1 JGQGDUURWUDSDW-UHFFFAOYSA-N 0.000 claims 2
- 229910052779 Neodymium Inorganic materials 0.000 claims 2
- 229910052772 Samarium Inorganic materials 0.000 claims 2
- 229910052771 Terbium Inorganic materials 0.000 claims 2
- 229910052776 Thorium Inorganic materials 0.000 claims 2
- 229910052775 Thulium Inorganic materials 0.000 claims 2
- 229910052770 Uranium Inorganic materials 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 229910052769 Ytterbium Inorganic materials 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 210000001772 blood platelet Anatomy 0.000 claims 2
- 229910052793 cadmium Inorganic materials 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229910052804 chromium Inorganic materials 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 229920001436 collagen Polymers 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 238000003745 diagnosis Methods 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 238000009472 formulation Methods 0.000 claims 2
- 229910052737 gold Inorganic materials 0.000 claims 2
- 229910052735 hafnium Inorganic materials 0.000 claims 2
- 125000005027 hydroxyaryl group Chemical group 0.000 claims 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 208000014674 injury Diseases 0.000 claims 2
- 238000012977 invasive surgical procedure Methods 0.000 claims 2
- 229910052741 iridium Inorganic materials 0.000 claims 2
- 229910052746 lanthanum Inorganic materials 0.000 claims 2
- 229910052745 lead Inorganic materials 0.000 claims 2
- 229910052749 magnesium Inorganic materials 0.000 claims 2
- 229910052748 manganese Inorganic materials 0.000 claims 2
- 238000013507 mapping Methods 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229910052759 nickel Inorganic materials 0.000 claims 2
- 229940055577 oleyl alcohol Drugs 0.000 claims 2
- XMLQWXUVTXCDDL-UHFFFAOYSA-N oleyl alcohol Natural products CCCCCCC=CCCCCCCCCCCO XMLQWXUVTXCDDL-UHFFFAOYSA-N 0.000 claims 2
- 229940067082 pentetate Drugs 0.000 claims 2
- 229960003330 pentetic acid Drugs 0.000 claims 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- 229910052698 phosphorus Inorganic materials 0.000 claims 2
- 230000035479 physiological effects, processes and functions Effects 0.000 claims 2
- 229910052697 platinum Inorganic materials 0.000 claims 2
- 230000008569 process Effects 0.000 claims 2
- 229910052703 rhodium Inorganic materials 0.000 claims 2
- 229910052710 silicon Inorganic materials 0.000 claims 2
- 229910052709 silver Inorganic materials 0.000 claims 2
- 210000002027 skeletal muscle Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 230000006641 stabilisation Effects 0.000 claims 2
- 238000011105 stabilization Methods 0.000 claims 2
- 229910052713 technetium Inorganic materials 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- RRBYUSWBLVXTQN-UHFFFAOYSA-N tricyclene Chemical group C12CC3CC2C1(C)C3(C)C RRBYUSWBLVXTQN-UHFFFAOYSA-N 0.000 claims 2
- 229910052721 tungsten Inorganic materials 0.000 claims 2
- 229910052720 vanadium Inorganic materials 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 229910052726 zirconium Inorganic materials 0.000 claims 2
- HMSMOZAIMDNRBW-UHFFFAOYSA-N 100572-96-1 Chemical compound C1=CC2=NC1=CC=C(N1)C=CC1=C(N1)C=CC1=CC=C1C=CC2=N1 HMSMOZAIMDNRBW-UHFFFAOYSA-N 0.000 claims 1
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 claims 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000035143 Bacterial infection Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 229940123150 Chelating agent Drugs 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- 208000032544 Cicatrix Diseases 0.000 claims 1
- 208000034656 Contusions Diseases 0.000 claims 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 229940097420 Diuretic Drugs 0.000 claims 1
- 108010014258 Elastin Proteins 0.000 claims 1
- 102000016942 Elastin Human genes 0.000 claims 1
- 206010015218 Erythema multiforme Diseases 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010067306 Fibronectins Proteins 0.000 claims 1
- 102000016359 Fibronectins Human genes 0.000 claims 1
- 238000000305 Fourier transform infrared microscopy Methods 0.000 claims 1
- 206010017533 Fungal infection Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010020843 Hyperthermia Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 108010006035 Metalloproteases Proteins 0.000 claims 1
- 102000005741 Metalloproteases Human genes 0.000 claims 1
- 206010062575 Muscle contracture Diseases 0.000 claims 1
- 208000031888 Mycoses Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 208000007256 Nevus Diseases 0.000 claims 1
- 206010048724 Pericardial fibrosis Diseases 0.000 claims 1
- 102000016611 Proteoglycans Human genes 0.000 claims 1
- 108010067787 Proteoglycans Proteins 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 238000001069 Raman spectroscopy Methods 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010040954 Skin wrinkling Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 208000024248 Vascular System injury Diseases 0.000 claims 1
- 208000012339 Vascular injury Diseases 0.000 claims 1
- 206010072810 Vascular wall hypertrophy Diseases 0.000 claims 1
- 108700005077 Viral Genes Proteins 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 108010031318 Vitronectin Proteins 0.000 claims 1
- 102100035140 Vitronectin Human genes 0.000 claims 1
- 208000000260 Warts Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 238000004458 analytical method Methods 0.000 claims 1
- 230000003872 anastomosis Effects 0.000 claims 1
- 229940035674 anesthetics Drugs 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 238000002583 angiography Methods 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000001028 anti-proliverative effect Effects 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 230000001147 anti-toxic effect Effects 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000000611 antibody drug conjugate Substances 0.000 claims 1
- 229940049595 antibody-drug conjugate Drugs 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 229940127218 antiplatelet drug Drugs 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000003305 autocrine Effects 0.000 claims 1
- 208000022362 bacterial infectious disease Diseases 0.000 claims 1
- 229960001212 bacterial vaccine Drugs 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 230000003115 biocidal effect Effects 0.000 claims 1
- 230000033228 biological regulation Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000010836 blood and blood product Substances 0.000 claims 1
- 229940125691 blood product Drugs 0.000 claims 1
- 210000004204 blood vessel Anatomy 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 150000007942 carboxylates Chemical class 0.000 claims 1
- 229940097217 cardiac glycoside Drugs 0.000 claims 1
- 239000002368 cardiac glycoside Substances 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 210000000845 cartilage Anatomy 0.000 claims 1
- 230000008859 change Effects 0.000 claims 1
- 239000002738 chelating agent Substances 0.000 claims 1
- 238000002512 chemotherapy Methods 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 210000002808 connective tissue Anatomy 0.000 claims 1
- 230000008602 contraction Effects 0.000 claims 1
- 208000006111 contracture Diseases 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- LYNARWYQOUZXDY-UHFFFAOYSA-N corrole Chemical compound N1C(C=C2NC(=CC=3NC4=CC=3)C=C2)=CC=C1C=C1C=CC4=N1 LYNARWYQOUZXDY-UHFFFAOYSA-N 0.000 claims 1
- 238000004132 cross linking Methods 0.000 claims 1
- 238000005520 cutting process Methods 0.000 claims 1
- 229930182912 cyclosporin Natural products 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 239000008367 deionised water Substances 0.000 claims 1
- 229910021641 deionized water Inorganic materials 0.000 claims 1
- 230000008021 deposition Effects 0.000 claims 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229920002549 elastin Polymers 0.000 claims 1
- 238000002091 elastography Methods 0.000 claims 1
- 230000005670 electromagnetic radiation Effects 0.000 claims 1
- 238000010894 electron beam technology Methods 0.000 claims 1
- 238000010828 elution Methods 0.000 claims 1
- 230000003073 embolic effect Effects 0.000 claims 1
- 239000000839 emulsion Substances 0.000 claims 1
- 238000005538 encapsulation Methods 0.000 claims 1
- 230000002124 endocrine Effects 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 210000003038 endothelium Anatomy 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 239000003527 fibrinolytic agent Substances 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000005095 gastrointestinal system Anatomy 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 239000003193 general anesthetic agent Substances 0.000 claims 1
- 229910052732 germanium Inorganic materials 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 229940125672 glycoprotein IIb/IIIa inhibitor Drugs 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 230000012010 growth Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000003779 hair growth Effects 0.000 claims 1
- 230000035876 healing Effects 0.000 claims 1
- 229940025294 hemin Drugs 0.000 claims 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 230000035873 hypermotility Effects 0.000 claims 1
- 208000000069 hyperpigmentation Diseases 0.000 claims 1
- 230000003810 hyperpigmentation Effects 0.000 claims 1
- 230000036031 hyperthermia Effects 0.000 claims 1
- 238000003384 imaging method Methods 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 229940121354 immunomodulator Drugs 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229960003444 immunosuppressant agent Drugs 0.000 claims 1
- 230000001861 immunosuppressant effect Effects 0.000 claims 1
- 239000003018 immunosuppressive agent Substances 0.000 claims 1
- 230000002637 immunotoxin Effects 0.000 claims 1
- 239000002596 immunotoxin Substances 0.000 claims 1
- 229940051026 immunotoxin Drugs 0.000 claims 1
- 231100000608 immunotoxin Toxicity 0.000 claims 1
- 229940047124 interferons Drugs 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000002608 intravascular ultrasound Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960003284 iron Drugs 0.000 claims 1
- 238000000608 laser ablation Methods 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 210000002540 macrophage Anatomy 0.000 claims 1
- 239000011159 matrix material Substances 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 claims 1
- CQKDGYMHYLBWTQ-UHFFFAOYSA-N methyl 3-[8,13-diethyl-18-(3-methoxy-3-oxopropyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoate Chemical compound N1C2=C(C)C(CC)=C1C=C(N1)C(C)=C(CC)C1=CC(C(C)=C1CCC(=O)OC)=NC1=CC(C(CCC(=O)OC)=C1C)=NC1=C2 CQKDGYMHYLBWTQ-UHFFFAOYSA-N 0.000 claims 1
- 239000000693 micelle Substances 0.000 claims 1
- 239000004005 microsphere Substances 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 210000000651 myofibroblast Anatomy 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 230000017074 necrotic cell death Effects 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 238000012014 optical coherence tomography Methods 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 claims 1
- 230000003076 paracrine Effects 0.000 claims 1
- 230000035515 penetration Effects 0.000 claims 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000002974 pharmacogenomic effect Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000006187 pill Substances 0.000 claims 1
- 230000035935 pregnancy Effects 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 230000001012 protector Effects 0.000 claims 1
- 238000000190 proton-induced X-ray emission spectroscopy Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000009467 reduction Effects 0.000 claims 1
- 230000008439 repair process Effects 0.000 claims 1
- 230000010076 replication Effects 0.000 claims 1
- 210000004994 reproductive system Anatomy 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 230000036573 scar formation Effects 0.000 claims 1
- 230000037387 scars Effects 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 206010040872 skin infection Diseases 0.000 claims 1
- 201000010153 skin papilloma Diseases 0.000 claims 1
- 208000031019 skin pigmentation disease Diseases 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 229930002534 steroid glycoside Natural products 0.000 claims 1
- 239000003270 steroid hormone Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000000758 substrate Substances 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- YKENVNAJIQUGKU-UHFFFAOYSA-N tetraazaporphin Chemical class C=1C(C=N2)=NC2=NC(NN2)=NC2=CC(C=C2)=NC2=CC2=NC=1C=C2 YKENVNAJIQUGKU-UHFFFAOYSA-N 0.000 claims 1
- 230000004797 therapeutic response Effects 0.000 claims 1
- 229960000103 thrombolytic agent Drugs 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 claims 1
- 238000003325 tomography Methods 0.000 claims 1
- 238000002604 ultrasonography Methods 0.000 claims 1
- 230000002485 urinary effect Effects 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 229940124549 vasodilator Drugs 0.000 claims 1
- 239000003071 vasodilator agent Substances 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 229960004854 viral vaccine Drugs 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29534501P | 2001-05-31 | 2001-05-31 | |
| PCT/US2002/017180 WO2002096366A2 (en) | 2001-05-31 | 2002-05-31 | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004532251A JP2004532251A (ja) | 2004-10-21 |
| JP2004532251A5 true JP2004532251A5 (enExample) | 2006-05-18 |
Family
ID=23137301
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002592879A Pending JP2004532251A (ja) | 2001-05-31 | 2002-05-31 | 光線力学療法で使用のメタロテトラピロール系光増感剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US6827926B2 (enExample) |
| EP (1) | EP1401506A4 (enExample) |
| JP (1) | JP2004532251A (enExample) |
| AU (1) | AU2002344234B2 (enExample) |
| CA (1) | CA2448562A1 (enExample) |
| WO (1) | WO2002096366A2 (enExample) |
Families Citing this family (149)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE552260T1 (de) | 1999-01-25 | 2012-04-15 | Nat Jewish Health | Substituierte porphyrine und deren therapeutische verwendung |
| US20030032634A1 (en) * | 2001-06-01 | 2003-02-13 | Piganelli Jon D. | Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance |
| US7097826B2 (en) * | 1999-12-23 | 2006-08-29 | Health Research, Inc. | Chlorin and bacteriochlorin-based difunctional aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals |
| US6750037B2 (en) | 1999-12-27 | 2004-06-15 | Edwin L. Adair | Method of cancer screening primarily utilizing non-invasive cell collection, fluorescence detection techniques, and radio tracing detection techniques |
| US20040073277A1 (en) * | 2002-04-05 | 2004-04-15 | Geronemus Roy G. | High fluence rate activation of photosensitizers for dermatological applications |
| DE60307545T2 (de) * | 2002-06-21 | 2007-10-04 | Adair, Edwin L., Castle Pines Village | Anwendung von Metalloporphyrinen zur Behandlung von Arteriosklerose |
| US20050163821A1 (en) * | 2002-08-02 | 2005-07-28 | Hsing-Wen Sung | Drug-eluting Biodegradable Stent and Delivery Means |
| US20040077621A1 (en) * | 2002-08-08 | 2004-04-22 | Academia Sinica | Antioxidants |
| GB2397067B (en) * | 2002-12-23 | 2005-05-11 | Destiny Pharma Ltd | Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation |
| US7250045B2 (en) | 2003-02-25 | 2007-07-31 | Spectragenics, Inc. | Self-contained, eye-safe hair-regrowth-inhibition apparatus and method |
| JP4361081B2 (ja) * | 2003-02-25 | 2009-11-11 | トリア ビューティ インコーポレイテッド | 目に安全な皮膚病学的処置装置 |
| JP2006518614A (ja) * | 2003-02-25 | 2006-08-17 | スペクトラジェニクス インコーポレイテッド | ニキビ処置装置および方法 |
| US7118563B2 (en) * | 2003-02-25 | 2006-10-10 | Spectragenics, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
| EP2604216B1 (en) | 2003-02-25 | 2018-08-22 | Tria Beauty, Inc. | Self-contained, diode-laser-based dermatologic treatment apparatus |
| US7981111B2 (en) | 2003-02-25 | 2011-07-19 | Tria Beauty, Inc. | Method and apparatus for the treatment of benign pigmented lesions |
| US7413567B2 (en) * | 2003-02-25 | 2008-08-19 | Spectragenics, Inc. | Optical sensor and method for identifying the presence of skin |
| WO2004080279A2 (en) * | 2003-03-06 | 2004-09-23 | Spectragenics, Inc. | In the patent cooperation treaty application for patent |
| WO2005000854A2 (en) * | 2003-06-06 | 2005-01-06 | Eukarion, Inc. | Orally bioavailable low molecular weight metalloporphyrins as antioxidants |
| DE202004021941U1 (de) | 2003-09-12 | 2013-05-13 | Vessix Vascular, Inc. | Auswählbare exzentrische Remodellierung und/oder Ablation von atherosklerotischem Material |
| US7553326B2 (en) * | 2003-11-24 | 2009-06-30 | Sweet Richard M | Method and apparatus for preventing dialysis graft intimal hyperplasia |
| US20050171436A1 (en) * | 2004-01-09 | 2005-08-04 | Clarke Richard H. | Raman spectroscopy for monitoring drug-eluting medical devices |
| EP2384744A1 (en) * | 2004-01-14 | 2011-11-09 | Gilead Sciences, Inc. | Lipid-based dispersions useful for drug delivery |
| US8777935B2 (en) | 2004-02-25 | 2014-07-15 | Tria Beauty, Inc. | Optical sensor and method for identifying the presence of skin |
| GB2415372A (en) | 2004-06-23 | 2005-12-28 | Destiny Pharma Ltd | Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent |
| US8153784B2 (en) * | 2004-07-07 | 2012-04-10 | The General Hospital Corporation | Imaging of enzyme activity |
| GB0415663D0 (en) * | 2004-07-13 | 2004-08-18 | Psimei Pharmaceuticals Plc | Compound |
| US8396548B2 (en) | 2008-11-14 | 2013-03-12 | Vessix Vascular, Inc. | Selective drug delivery in a lumen |
| US9713730B2 (en) | 2004-09-10 | 2017-07-25 | Boston Scientific Scimed, Inc. | Apparatus and method for treatment of in-stent restenosis |
| US7524671B2 (en) * | 2005-01-27 | 2009-04-28 | Prescient Medical, Inc. | Handheld raman blood analyzer |
| US7651851B2 (en) * | 2005-01-27 | 2010-01-26 | Prescient Medical, Inc. | Handheld Raman body fluid analyzer |
| US7688440B2 (en) | 2005-01-27 | 2010-03-30 | Prescient Medical, Inc. | Raman spectroscopic test strip systems |
| US8066759B2 (en) * | 2005-02-04 | 2011-11-29 | Boston Scientific Scimed, Inc. | Resonator for medical device |
| WO2006089122A2 (en) * | 2005-02-18 | 2006-08-24 | North Carolina State University | De novo synthesis of bacteriochlorins |
| US20060222592A1 (en) * | 2005-04-05 | 2006-10-05 | Clemens Burda | Nanoparticles and methods of manufacturing nanoparticles for electronic and non-electronic applications |
| US7595469B2 (en) * | 2005-05-24 | 2009-09-29 | Boston Scientific Scimed, Inc. | Resonator for medical device |
| US7279664B2 (en) * | 2005-07-26 | 2007-10-09 | Boston Scientific Scimed, Inc. | Resonator for medical device |
| US7304277B2 (en) * | 2005-08-23 | 2007-12-04 | Boston Scientific Scimed, Inc | Resonator with adjustable capacitor for medical device |
| US7524282B2 (en) * | 2005-08-29 | 2009-04-28 | Boston Scientific Scimed, Inc. | Cardiac sleeve apparatus, system and method of use |
| EP1762248A1 (en) * | 2005-09-09 | 2007-03-14 | CORIT Consorzio per la Ricerca sul | Use of cobalt porphyrins in joint therapy with an immunosuppressant drug for treatment of transplant patients or autoimmune disorders |
| US8097609B2 (en) * | 2005-10-20 | 2012-01-17 | North Carolina State University | Swallowtail motifs for imparting water solubility to porphyrinic compounds |
| EP1779891A1 (en) * | 2005-10-28 | 2007-05-02 | Abdula Kurkayev | Method of activating a photosensitizer |
| WO2007056440A1 (en) * | 2005-11-07 | 2007-05-18 | Titan Pharmaceuticals, Inc. | Treatment and prevention of adverse liver conditions using gallium |
| US7423496B2 (en) * | 2005-11-09 | 2008-09-09 | Boston Scientific Scimed, Inc. | Resonator with adjustable capacitance for medical device |
| US8170643B2 (en) * | 2005-11-22 | 2012-05-01 | Bsd Medical Corporation | System and method for irradiating a target with electromagnetic radiation to produce a heated region |
| US8207329B2 (en) * | 2005-11-30 | 2012-06-26 | North Carolina State University | Synthesis of chlorins and phorbines with enhanced red spectral features |
| WO2007064841A2 (en) | 2005-11-30 | 2007-06-07 | North Carolina State University | Porphyrinic compounds for use in flow cytometry |
| US20090326435A1 (en) * | 2006-05-02 | 2009-12-31 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like varicose or spider veins |
| US8019435B2 (en) | 2006-05-02 | 2011-09-13 | Boston Scientific Scimed, Inc. | Control of arterial smooth muscle tone |
| US20070299431A1 (en) * | 2006-05-02 | 2007-12-27 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| US7465312B2 (en) * | 2006-05-02 | 2008-12-16 | Green Medical, Inc. | Systems and methods for treating superficial venous malformations like spider veins |
| EP2076194B1 (en) | 2006-10-18 | 2013-04-24 | Vessix Vascular, Inc. | System for inducing desirable temperature effects on body tissue |
| EP2076193A4 (en) | 2006-10-18 | 2010-02-03 | Minnow Medical Inc | MATCHED RF-ENERGY AND ELECTRO-TISSUE CHARACTERIZATION FOR THE SELECTIVE TREATMENT OF TARGET TISSUE |
| ES2560006T3 (es) | 2006-10-18 | 2016-02-17 | Vessix Vascular, Inc. | Inducción de efectos de temperatura deseables sobre tejido corporal |
| FR2914302A1 (fr) * | 2007-03-30 | 2008-10-03 | Sanofi Pasteur Sa | Procede de preparation de derives de porphyrine, telle que la protoporphyrine (ix) et intermediaire de synthese |
| WO2009006075A2 (en) * | 2007-06-29 | 2009-01-08 | Board Of Regents, The University Of Texas System | Functionalized expanded porphyrins |
| JP5595270B2 (ja) * | 2007-08-08 | 2014-09-24 | トリア ビューティ インコーポレイテッド | 皮膚検知のための静電容量型センシング方法及び装置 |
| EP3300744A1 (en) | 2008-04-04 | 2018-04-04 | Immunolight, Llc. | Non-invasive systems and methods for in-situ photobiomodulation |
| US20090275548A1 (en) * | 2008-04-18 | 2009-11-05 | Thomas Lewis | Compounds and methods for activated therapy |
| EP2268198A4 (en) | 2008-04-25 | 2014-10-15 | Tria Beauty Inc | OPTICAL DETECTOR AND METHOD FOR IDENTIFYING THE PRESENCE OF SKIN AND PIGMENTATION OF THE SKIN |
| ES2600469T3 (es) | 2008-05-23 | 2017-02-09 | National Jewish Health | Un compuesto para su uso en el tratamiento de lesiones asociadas con la exposición al gas fosgeno o al gas de cloro |
| EP2323693B1 (en) * | 2008-07-30 | 2017-11-08 | Nitto Denko Corporation | Drug carriers |
| US8416405B2 (en) | 2008-08-08 | 2013-04-09 | Chemimage Corporation | Raman chemical imaging of implantable drug delivery devices |
| EP2348848A4 (en) * | 2008-10-03 | 2012-03-07 | Charlotte Mecklenburg Hospital | METHOD FOR TREATING HEPATITIS C INFECTION WITH METALOPORPHYRINES |
| CN102271603A (zh) | 2008-11-17 | 2011-12-07 | 明诺医学股份有限公司 | 得知或未得知组织形态的选择性能量积累 |
| US8802074B2 (en) | 2008-11-26 | 2014-08-12 | Board Of Regents, The University Of Texas System | Polymers functionalized with ion-specific recognition elements |
| US8709473B1 (en) | 2009-01-28 | 2014-04-29 | Abbott Cardiovascular Systems Inc. | Method of targeting hydrophobic drugs to vascular lesions |
| US20100227799A1 (en) * | 2009-03-09 | 2010-09-09 | Medtronic Vascular, Inc. | Simultaneous photodynamic therapy and photo induced polymerization |
| RU2411243C1 (ru) * | 2009-07-09 | 2011-02-10 | Государственное образовательное учреждение высшего профессионального образования "Московская государственная академия тонкой химической технологии имени М.В. Ломоносова" | Иттербиевый комплекс дикалиевой соли 2,4-диметоксигематопорфирина ix как флуоресцентная метка для ранней диагностики рака |
| KR20130108067A (ko) | 2010-04-09 | 2013-10-02 | 베식스 바스큘라 인코포레이티드 | 조직 치료를 위한 발전 및 제어 장치 |
| US9192790B2 (en) | 2010-04-14 | 2015-11-24 | Boston Scientific Scimed, Inc. | Focused ultrasonic renal denervation |
| US8473067B2 (en) | 2010-06-11 | 2013-06-25 | Boston Scientific Scimed, Inc. | Renal denervation and stimulation employing wireless vascular energy transfer arrangement |
| US9358365B2 (en) | 2010-07-30 | 2016-06-07 | Boston Scientific Scimed, Inc. | Precision electrode movement control for renal nerve ablation |
| US9408661B2 (en) | 2010-07-30 | 2016-08-09 | Patrick A. Haverkost | RF electrodes on multiple flexible wires for renal nerve ablation |
| US9084609B2 (en) | 2010-07-30 | 2015-07-21 | Boston Scientific Scime, Inc. | Spiral balloon catheter for renal nerve ablation |
| US9463062B2 (en) | 2010-07-30 | 2016-10-11 | Boston Scientific Scimed, Inc. | Cooled conductive balloon RF catheter for renal nerve ablation |
| US9155589B2 (en) | 2010-07-30 | 2015-10-13 | Boston Scientific Scimed, Inc. | Sequential activation RF electrode set for renal nerve ablation |
| US8974451B2 (en) | 2010-10-25 | 2015-03-10 | Boston Scientific Scimed, Inc. | Renal nerve ablation using conductive fluid jet and RF energy |
| US9220558B2 (en) | 2010-10-27 | 2015-12-29 | Boston Scientific Scimed, Inc. | RF renal denervation catheter with multiple independent electrodes |
| US9028485B2 (en) | 2010-11-15 | 2015-05-12 | Boston Scientific Scimed, Inc. | Self-expanding cooling electrode for renal nerve ablation |
| US9089350B2 (en) | 2010-11-16 | 2015-07-28 | Boston Scientific Scimed, Inc. | Renal denervation catheter with RF electrode and integral contrast dye injection arrangement |
| US9668811B2 (en) | 2010-11-16 | 2017-06-06 | Boston Scientific Scimed, Inc. | Minimally invasive access for renal nerve ablation |
| US9326751B2 (en) | 2010-11-17 | 2016-05-03 | Boston Scientific Scimed, Inc. | Catheter guidance of external energy for renal denervation |
| US9060761B2 (en) | 2010-11-18 | 2015-06-23 | Boston Scientific Scime, Inc. | Catheter-focused magnetic field induced renal nerve ablation |
| US9023034B2 (en) | 2010-11-22 | 2015-05-05 | Boston Scientific Scimed, Inc. | Renal ablation electrode with force-activatable conduction apparatus |
| US9192435B2 (en) | 2010-11-22 | 2015-11-24 | Boston Scientific Scimed, Inc. | Renal denervation catheter with cooled RF electrode |
| US20120157993A1 (en) | 2010-12-15 | 2012-06-21 | Jenson Mark L | Bipolar Off-Wall Electrode Device for Renal Nerve Ablation |
| DE102010056443A1 (de) * | 2010-12-28 | 2012-06-28 | Universität Bremen | Chlorin-Derivate und deren Verwendung |
| US9220561B2 (en) | 2011-01-19 | 2015-12-29 | Boston Scientific Scimed, Inc. | Guide-compatible large-electrode catheter for renal nerve ablation with reduced arterial injury |
| JP5885743B2 (ja) * | 2011-07-01 | 2016-03-15 | Ｓｂｉファーマ株式会社 | 光増感剤又は５−アミノレブリン酸類を用いる光線力学的治療 |
| EP2729175B1 (en) | 2011-07-08 | 2021-12-01 | Duke University | System for light stimulation within a medium |
| CN103813745B (zh) | 2011-07-20 | 2016-06-29 | 波士顿科学西美德公司 | 用以可视化、对准和消融神经的经皮装置及方法 |
| US9186209B2 (en) | 2011-07-22 | 2015-11-17 | Boston Scientific Scimed, Inc. | Nerve modulation system having helical guide |
| EP2765942B1 (en) | 2011-10-10 | 2016-02-24 | Boston Scientific Scimed, Inc. | Medical devices including ablation electrodes |
| WO2013055815A1 (en) | 2011-10-11 | 2013-04-18 | Boston Scientific Scimed, Inc. | Off -wall electrode device for nerve modulation |
| US9420955B2 (en) | 2011-10-11 | 2016-08-23 | Boston Scientific Scimed, Inc. | Intravascular temperature monitoring system and method |
| US9364284B2 (en) | 2011-10-12 | 2016-06-14 | Boston Scientific Scimed, Inc. | Method of making an off-wall spacer cage |
| US9162046B2 (en) | 2011-10-18 | 2015-10-20 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| WO2013059202A1 (en) | 2011-10-18 | 2013-04-25 | Boston Scientific Scimed, Inc. | Integrated crossing balloon catheter |
| EP2775948B1 (en) | 2011-11-08 | 2018-04-04 | Boston Scientific Scimed, Inc. | Ostial renal nerve ablation |
| US9119600B2 (en) | 2011-11-15 | 2015-09-01 | Boston Scientific Scimed, Inc. | Device and methods for renal nerve modulation monitoring |
| US9119632B2 (en) | 2011-11-21 | 2015-09-01 | Boston Scientific Scimed, Inc. | Deflectable renal nerve ablation catheter |
| US9265969B2 (en) | 2011-12-21 | 2016-02-23 | Cardiac Pacemakers, Inc. | Methods for modulating cell function |
| CA2861622C (en) | 2011-12-23 | 2020-10-27 | Vessix Vascular, Inc. | Methods and apparatuses for remodeling tissue of or adjacent to a body passage |
| WO2013101452A1 (en) | 2011-12-28 | 2013-07-04 | Boston Scientific Scimed, Inc. | Device and methods for nerve modulation using a novel ablation catheter with polymeric ablative elements |
| US9050106B2 (en) | 2011-12-29 | 2015-06-09 | Boston Scientific Scimed, Inc. | Off-wall electrode device and methods for nerve modulation |
| WO2013169927A1 (en) | 2012-05-08 | 2013-11-14 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices |
| US10321946B2 (en) | 2012-08-24 | 2019-06-18 | Boston Scientific Scimed, Inc. | Renal nerve modulation devices with weeping RF ablation balloons |
| WO2014043687A2 (en) | 2012-09-17 | 2014-03-20 | Boston Scientific Scimed, Inc. | Self-positioning electrode system and method for renal nerve modulation |
| WO2014047411A1 (en) | 2012-09-21 | 2014-03-27 | Boston Scientific Scimed, Inc. | System for nerve modulation and innocuous thermal gradient nerve block |
| US10549127B2 (en) | 2012-09-21 | 2020-02-04 | Boston Scientific Scimed, Inc. | Self-cooling ultrasound ablation catheter |
| CN104869930B (zh) | 2012-10-10 | 2020-12-25 | 波士顿科学国际有限公司 | 肾神经调制装置和方法 |
| WO2014143571A1 (en) | 2013-03-11 | 2014-09-18 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US9956033B2 (en) | 2013-03-11 | 2018-05-01 | Boston Scientific Scimed, Inc. | Medical devices for modulating nerves |
| US9808311B2 (en) | 2013-03-13 | 2017-11-07 | Boston Scientific Scimed, Inc. | Deflectable medical devices |
| JP6220044B2 (ja) | 2013-03-15 | 2017-10-25 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 腎神経アブレーションのための医療用デバイス |
| US10265122B2 (en) | 2013-03-15 | 2019-04-23 | Boston Scientific Scimed, Inc. | Nerve ablation devices and related methods of use |
| WO2014149690A2 (en) | 2013-03-15 | 2014-09-25 | Boston Scientific Scimed, Inc. | Medical devices and methods for treatment of hypertension that utilize impedance compensation |
| US9943365B2 (en) | 2013-06-21 | 2018-04-17 | Boston Scientific Scimed, Inc. | Renal denervation balloon catheter with ride along electrode support |
| JP2016524949A (ja) | 2013-06-21 | 2016-08-22 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 回転可能シャフトを有する腎神経アブレーション用医療装置 |
| US9707036B2 (en) | 2013-06-25 | 2017-07-18 | Boston Scientific Scimed, Inc. | Devices and methods for nerve modulation using localized indifferent electrodes |
| JP6204579B2 (ja) | 2013-07-01 | 2017-09-27 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 腎神経アブレーション用医療器具 |
| EP3019105B1 (en) | 2013-07-11 | 2017-09-13 | Boston Scientific Scimed, Inc. | Devices for nerve modulation |
| EP3019106A1 (en) | 2013-07-11 | 2016-05-18 | Boston Scientific Scimed, Inc. | Medical device with stretchable electrode assemblies |
| US9925001B2 (en) | 2013-07-19 | 2018-03-27 | Boston Scientific Scimed, Inc. | Spiral bipolar electrode renal denervation balloon |
| CN105392435B (zh) | 2013-07-22 | 2018-11-09 | 波士顿科学国际有限公司 | 具有扭绞球囊的肾神经消融导管 |
| WO2015013205A1 (en) | 2013-07-22 | 2015-01-29 | Boston Scientific Scimed, Inc. | Medical devices for renal nerve ablation |
| JP6159888B2 (ja) | 2013-08-22 | 2017-07-05 | ボストン サイエンティフィック サイムド，インコーポレイテッドＢｏｓｔｏｎ Ｓｃｉｅｎｔｉｆｉｃ Ｓｃｉｍｅｄ，Ｉｎｃ． | 腎神経変調バルーンへの接着性を向上させたフレキシブル回路 |
| CN105555218B (zh) | 2013-09-04 | 2019-01-15 | 波士顿科学国际有限公司 | 具有冲洗和冷却能力的射频(rf)球囊导管 |
| CN105530885B (zh) | 2013-09-13 | 2020-09-22 | 波士顿科学国际有限公司 | 具有气相沉积覆盖层的消融球囊 |
| US9687166B2 (en) | 2013-10-14 | 2017-06-27 | Boston Scientific Scimed, Inc. | High resolution cardiac mapping electrode array catheter |
| US11246654B2 (en) | 2013-10-14 | 2022-02-15 | Boston Scientific Scimed, Inc. | Flexible renal nerve ablation devices and related methods of use and manufacture |
| CN105636537B (zh) | 2013-10-15 | 2018-08-17 | 波士顿科学国际有限公司 | 医疗器械球囊 |
| US9770606B2 (en) | 2013-10-15 | 2017-09-26 | Boston Scientific Scimed, Inc. | Ultrasound ablation catheter with cooling infusion and centering basket |
| CN105636538B (zh) | 2013-10-18 | 2019-01-15 | 波士顿科学国际有限公司 | 具有柔性导线的球囊导管及其使用和制造的相关方法 |
| EP3060153A1 (en) | 2013-10-25 | 2016-08-31 | Boston Scientific Scimed, Inc. | Embedded thermocouple in denervation flex circuit |
| EP3091922B1 (en) | 2014-01-06 | 2018-10-17 | Boston Scientific Scimed, Inc. | Tear resistant flex circuit assembly |
| WO2015119890A1 (en) | 2014-02-04 | 2015-08-13 | Boston Scientific Scimed, Inc. | Alternative placement of thermal sensors on bipolar electrode |
| US11000679B2 (en) | 2014-02-04 | 2021-05-11 | Boston Scientific Scimed, Inc. | Balloon protection and rewrapping devices and related methods of use |
| WO2016123841A1 (zh) * | 2015-02-03 | 2016-08-11 | 东南大学 | 老年痴呆和心脑血管疾病检测的多模态成像的制剂及应用 |
| US10035806B2 (en) | 2015-10-06 | 2018-07-31 | California Institute Of Technology | Derivatized corroles and metallocorroles and their use as imaging and therapeutic agents |
| RU2617045C1 (ru) * | 2016-03-02 | 2017-04-19 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский технологический университет" | Фармацевтическая композиция для люминесцентной диагностики патологических изменений кожи и слизистых оболочек |
| US10335608B2 (en) | 2016-04-20 | 2019-07-02 | Theralase Technologies, Inc. | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics |
| CN109575036B (zh) * | 2018-12-11 | 2020-09-22 | 怀化学院 | 金属血卟啉双醚二酯类化合物，催化剂及其制备方法以及环己烷催化氧化方法 |
| CN111848656B (zh) * | 2020-06-24 | 2023-03-14 | 天津大学 | 离子修饰的原卟啉镓化合物及其制备方法和应用 |
| EP4210756A4 (en) * | 2020-09-11 | 2025-12-31 | Pinnacle Biologics Inc | PHOTODYNAMIC THERAPY COMPOSITIONS AND THEIR METHODS OF USE |
| CN112402632B (zh) * | 2020-11-24 | 2022-01-07 | 南京大学 | 一种放疗增敏用纳米级配位聚合物及其制备方法和用途 |
| US11896852B2 (en) | 2020-12-21 | 2024-02-13 | Xerox Corporation | Closed-loop non-invasive transcranial stimulation and neural activity recording system and method |
| US12207930B2 (en) | 2020-12-21 | 2025-01-28 | Xerox Corporation | Non-invasive transcranial stimulation system and method using pre-recorded neurostimulation data |
| CN115945220B (zh) * | 2023-03-15 | 2023-05-30 | 四川大学 | 一种Ir金属基生物催化剂及其制备方法和用途 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE84036T1 (de) | 1985-10-23 | 1993-01-15 | Nihon Mediphysics Co Ltd | Porphyrinderivate, ihre herstellung und verwendung. |
| US5672334A (en) | 1991-01-16 | 1997-09-30 | Access Pharmaceuticals, Inc. | Invivo agents comprising cationic metal chelators with acidic saccharides and glycosaminoglycans |
| US5283255A (en) * | 1987-01-20 | 1994-02-01 | The University Of British Columbia | Wavelength-specific cytotoxic agents |
| US5552134A (en) | 1988-01-11 | 1996-09-03 | University Of Toledo | Uses of benzochlorins, verdins and porphyrin derivatives and of compositions containing such benzochlorins, verdins and porphyrin derivatives |
| JP3191223B2 (ja) | 1991-10-04 | 2001-07-23 | 株式会社光ケミカル研究所 | ポルフィリン誘導体とその用途 |
| DE4232925A1 (de) * | 1992-09-28 | 1994-03-31 | Diagnostikforschung Inst | 3-,8-substituierte Deuteroporphyrinderivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung |
| US5405957A (en) | 1992-10-30 | 1995-04-11 | The University Of British Columbia | Wavelength-specific photosensitive compounds and expanded porphyrin-like compounds and methods of use |
| US5948771A (en) * | 1996-01-31 | 1999-09-07 | The Trustees Of Columbia University In The City Of New York | Method for treating heart failure using tetrapyrroles and metallotetrapyrroles |
| AU6028598A (en) | 1997-01-09 | 1998-08-03 | Emory University | Non-iron metalloporphyrins and methods of use |
| HU221754B1 (hu) * | 1997-05-07 | 2002-12-28 | Qlt Inc | Fotoaktív szerekként alkalmazható monohidrobenzoporfirin származékok etilénglikol észterei |
| US5880145A (en) * | 1997-05-07 | 1999-03-09 | The University Of British Columbia | Class of benzoporphyrin derivative photoactive compounds |
| US6136841A (en) | 1998-06-02 | 2000-10-24 | Schering Aktiengesellschaft | 3-, 8-substituted deuteroporphyrin derivatives, pharmaceutical agents that contain the latter, process for their production and their use in photodynamic therapy and MRI diagnosis |
| WO2001035996A2 (en) * | 1999-11-17 | 2001-05-25 | Qlt Inc. | Use of pdt to inhibit intimal hyperplasia |
| EP1311302A2 (en) * | 2000-06-21 | 2003-05-21 | Bristol-Myers Squibb Pharma Company | Pharmaceuticals for the imaging of angiogenic disorders |
| CA2448570A1 (en) * | 2001-05-31 | 2002-12-05 | Miravant Pharmaceuticals, Inc. | Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and mri diagnosis |
| EP1279676A1 (en) * | 2001-07-19 | 2003-01-29 | Institut Curie | Porphyrin derivatives for photodynamic therapy |
| AU2002336636A1 (en) * | 2001-10-03 | 2003-04-14 | Miravant Pharmaceuticals, Inc. | Photosensitizing carbamate derivatives |
| US20050020559A1 (en) * | 2001-10-03 | 2005-01-27 | Robinson Byron C | Chlorin photosensitizing agents for use in photodynamic therapy |
-
2002
- 2002-05-31 CA CA002448562A patent/CA2448562A1/en not_active Abandoned
- 2002-05-31 EP EP02744204A patent/EP1401506A4/en not_active Withdrawn
- 2002-05-31 WO PCT/US2002/017180 patent/WO2002096366A2/en not_active Ceased
- 2002-05-31 AU AU2002344234A patent/AU2002344234B2/en not_active Ceased
- 2002-05-31 JP JP2002592879A patent/JP2004532251A/ja active Pending
- 2002-05-31 US US10/159,005 patent/US6827926B2/en not_active Expired - Fee Related
-
2004
- 2004-10-18 US US10/965,849 patent/US20050137180A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004532251A5 (enExample) | ||
| US6827926B2 (en) | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy | |
| US10780045B2 (en) | Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof | |
| US11826426B2 (en) | Nanoscale metal-organic layers and metal-organic nanoplates for x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | |
| AU2002344234A1 (en) | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy | |
| US20180153796A1 (en) | Nanoparticles for photodynamic therapy, x-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof | |
| EP2705855B1 (en) | Photodynamic therapy or diagnostic agent, using infrared-spectrum light | |
| JP2009529533A (ja) | 光活性の化合物および組成物、ならびにそれらの使用方法 | |
| EP3292129B1 (en) | Low molecular weight halogenated porphyrine carboxamide chlorin and bacteriochlorin derivatives for use in photodynamic therapy for treating cancer | |
| CN113461697B (zh) | 一种二氢卟吩类化合物及其制备方法和用途 | |
| EP0644759A4 (en) | PRODUCTION AND USE OF PORPHYRIN IMINES. | |
| Zhang et al. | Fluorinated porphyrin-based theranostics for dual imaging and chemo-photodynamic therapy | |
| CN1158284C (zh) | 卟啉衍生物及其用途 | |
| EP1567147B1 (en) | Water-soluble anionic bacteriochlorophyll derivatives and their uses | |
| JP2021535258A (ja) | シアニンベースをベースとするテロデンドリマー及び癌治療のための使用 | |
| CN1265039A (zh) | 泰克萨菲瑞在制备用于诊断和治疗眼部疾病的药物中的应用 | |
| JP2009528373A (ja) | チアジアゾール化合物および光線療法のためのその使用 | |
| WO2000001414A1 (en) | Use of texaphyrins in macrophage-mediated disease | |
| AU2008200847A1 (en) | Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy | |
| US20020115649A1 (en) | Use of texaphyrins in macrophage-mediated disease | |
| WO2021226849A1 (zh) | 一类免疫活性肽-胆绿素的缀合物、其制备方法及应用 | |
| Sivakumar et al. | Photodynamic Therapy: Progress in Fabrication | |
| HK1081858B (en) | Water-soluble anionic bacteriochlorophyll derivatives and their uses |